CJC-1295 + ipamorelin vs HGH: what the data shows

Key takeaways

• Recombinant HGH (somatropin) is an FDA-approved drug with defined indications (adult growth hormone deficiency, several pediatric short-stature causes, HIV-associated wasting and lipodystrophy); CJC-1295 and ipamorelin are not approved for any human use .
• CJC-1295 is a long-acting GHRH analog: in one small healthy-adult study a single dose raised average growth hormone about 46 percent and IGF-1 about 45 percent for roughly a week, with the natural pulse pattern preserved .
• Ipamorelin is a selective growth hormone secretagogue that releases GH without significantly raising cortisol, ACTH, or prolactin, but it has no published body-composition outcome trial in healthy adults .
• In the best controlled data for healthy older adults, growth hormone itself produced only about 2.1 kg less fat and 2.1 kg more lean mass, with more swelling, joint pain, carpal tunnel, and blood-sugar problems; the review said GH cannot be recommended as anti-aging therapy .
• All three are on the WADA banned list at all times, and distributing growth hormone for anything other than an FDA-authorized use is a federal crime under 21 USC 333(e) .

Skip to:

• What actually separates them
• What each one actually is
• What the human evidence shows
• What the bloodwork measures, and what it does not
• The legal and anti-doping reality
• The honest read

What actually separates them

Here is the side by side on the dimensions people actually weigh: what it is, what the evidence says, what it does to your bloodwork, and where it sits legally.

What each one actually is

Somatropin is recombinant human growth hormone: the actual 191-amino-acid hormone, made by recombinant DNA and injected directly. It has been an approved drug since the mid-1980s, and the label spells out who it is for and how it is dosed and monitored . When you inject somatropin you are adding hormone from outside the body.

CJC-1295 and ipamorelin work the other way around. They do not add growth hormone. They push your own pituitary to release more of it, through two different doors. CJC-1295 is an analog of GHRH, the hypothalamic signal that tells the pituitary to make GH. Ipamorelin is a small peptide that binds the ghrelin receptor, a separate switch that also triggers GH release. Stacking the two is the usual rationale: hit both signals at once.

CJC-1295 comes in two forms, and the difference matters. The long-acting version carries a drug-affinity-complex (DAC) tag that binds to albumin in the blood and stretches its action to about a week. The short-acting no-DAC version, often sold as modified GRF 1-29, clears in minutes to hours. The one published healthy-adult study used the long-acting form: a single injection raised average GH about 46 percent and IGF-1 about 45 percent, and notably the natural pulsatile release pattern was preserved rather than flattened .

Ipamorelin earned its place in the literature for being selective. The 1998 paper that introduced it called it the first selective growth hormone secretagogue, because it released GH without meaningfully raising cortisol, ACTH, or prolactin, the off-target hormones that older secretagogues like GHRP-6 dragged up with them . Its pharmacokinetics in humans were later modeled, so we know roughly how it behaves in the blood . What does not exist is a trial showing it changes body composition in healthy adults.

What the human evidence shows

Put the two sides on the same scale and the gap is obvious. Somatropin has decades of randomized trials, a defined indication set, and a documented adverse-event profile. The peptides have a handful of pharmacology papers and a marketing story.

Here is the part the sales copy skips. Even when you give actual growth hormone to healthy older adults, the payoff is small and comes with a tax. A systematic review pooling the controlled trials found that GH shifted body composition by roughly 2.1 kg of fat lost and 2.1 kg of lean mass gained, with weight basically unchanged, while significantly increasing soft-tissue swelling, joint pain, carpal tunnel syndrome, and the risk of impaired fasting glucose and diabetes. The authors concluded that growth hormone cannot be recommended as an anti-aging therapy .

That is the ceiling, not the floor, for what a GH-axis intervention does in people who are not deficient. CJC-1295 and ipamorelin aim to raise the same hormone less directly, so the best plausible case for them is a fraction of that already-modest effect, minus the controlled evidence that it happens at all. The one approved GHRH analog on the market, tesamorelin, only carries an indication for a specific population (HIV-associated visceral fat), and it got there through full Phase 3 trials, not forum consensus .

What the bloodwork measures, and what it does not

Most people running these compounds track one number: IGF-1. It is the right number to watch, because IGF-1 is the main downstream signal of growth hormone activity and it is far more stable in the blood than GH itself, which comes in pulses. Diagnosing actual GH deficiency is more involved than a single IGF-1 draw: clinical guidelines lean on GH stimulation testing alongside IGF-1, because IGF-1 alone misses cases and is influenced by age, nutrition, and liver health .

There is a trap in reading your own IGF-1, and it is not the kind people expect. The assays themselves disagree. A consensus statement on growth-hormone and IGF-1 testing found that different commercial kits can return meaningfully different IGF-1 values for the identical sample, and that converting to standardized scores using different reference sets widens the spread further . A number that looks like a big jump may partly be the lab, not the molecule.

The legal and anti-doping reality

The legal posture on growth hormone is unusually strict, and it is worth stating plainly. A 2005 JAMA clinical-and-legal review laid it out: federal law (21 USC 333(e)) makes it a crime to distribute growth hormone for any use other than one the FDA has authorized. Selling or supplying HGH for anti-aging, bodybuilding, or general wellness is not a gray area, it is a felony distribution statute .

CJC-1295 and ipamorelin sit in a different but not safer box. They are not approved drugs at all, so they are sold as research chemicals, which is the tell that no agency has vouched for their identity, purity, or dose. The contrast with an approved product is the whole point: somatropin has a DailyMed label that defines what is in the vial and who it is for , and these peptides have nothing equivalent.

For anyone subject to drug testing, the line is simple. Growth hormone, GHRH analogs like CJC-1295, and GH secretagogues like ipamorelin are all on the WADA prohibited list under section S2, banned at all times, in and out of competition . There is no microdose or timing window that makes them compliant in tested sport.

The honest read

Recombinant HGH and the CJC-1295 plus ipamorelin stack are not the same decision. Somatropin is a real drug with real indications, a real safety database, and a modest, well-characterized effect in people who are not deficient, alongside real downsides. The peptides are an attempt to raise the same hormone less directly, sold without the approval, the outcome trials, or the legal standing the drug has, and with the same anti-doping ban. If the goal is evidence and a known safety profile, the gap between the two is not close. If the goal is a legal, proven anti-aging shortcut, neither side delivers one .

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article. Growth-hormone-axis therapy, bloodwork interpretation, and any decision involving somatropin or GH secretagogues belong with a qualified clinician who can review your individual history and labs.

For how this article was sourced and reviewed, see Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 10 entries, all primary canon (PubMed, DailyMed, WADA), last reviewed 2026-05-29.

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.